# Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity

> **NCT06180616** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Royal North Shore Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Type 1 Diabetes Mellitus
- Overweight and Obesity

## Interventions

- **DRUG:** Tirzepatide

## Key facts

- **NCT ID:** NCT06180616
- **Lead sponsor:** Royal North Shore Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06180616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06180616, "Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06180616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*